title: [The present and future of AIDS chemotherapy].
abstract: As soon as the replication cycle of the virus of human immunodeficiency type 1 (HIV-1) was recognized, a number of antiretroviral drugs were developed which inhibit more or less successfully HIV-1 at different sites of its replication cycle. The first drug tested on patients was the nucleoside analogue inhibiting reverse transcriptase--azidothymidine (AZT). It still remains the basic drug of choice. Less well known are other drugs inhibiting HIV-1 at sites of adsorption on the target cell or in different stages of construction of new viral progenies. Combined therapy makes inhibition of HIV-1 at various sites of the replication cycle possible, a certain part is played also by the synergistic action of various drugs. This makes a reduction of dosage possible and thus also a reduction of their toxic action. The objective of research is a drug which will eradicate the virus completely and lead to permanent remission of the infection.
authors.affiliation: III. klinika infekcních a tropických nemocí, Praha.
authors.forename: M
authors.initials: M
authors.lastname: Stanková
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans
chemical_list: D000998:Antiviral Agents
vernacular_title: Soucasnost a budoucnost chemoterapie AIDS.